MedTrace Logo

CYP1A2 and ADORA2A Genotypes and Endurance Performance.

NCT06547307 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-08-09

No results posted yet for this study

Summary

The aim of this randomized, double-blind, placebo-controlled experiment will be to assess the potential effect of the selected gene polymorphism (CYP1A2, ADORA2A) on performance after caffeine ingestion.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Caffeine 2 mg

To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.

DIETARY_SUPPLEMENT

Caffeine 4 mg

To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.

DIETARY_SUPPLEMENT

Caffeine 0 mg

To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.

Sponsors & Collaborators

  • Masaryk University

    lead OTHER

Principal Investigators

  • Lucie Lipková · Masaryk University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-31
Primary Completion
2025-01-31
Completion
2025-03-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06547307 on ClinicalTrials.gov